Trump Administration Announces New Tariffs on Pharmaceuticals and Metals

President Donald Trump signed an executive order on Thursday, April 2, 2026, imposing tariffs of up to 100% on certain brand-name pharmaceuticals produced overseas. This move aims to incentivize drug companies to manufacture in the United States and lower drug prices for American consumers. Simultaneously, the administration adjusted tariffs on products containing steel and aluminum.

Pharmaceutical Tariffs: A Closer Look

The new tariffs target brand-name pharmaceuticals, with the potential for a 100% levy on those produced outside the U.S. However, the administration has outlined pathways for companies to mitigate or avoid these tariffs. Drug companies that commit to moving production to the United States will face a 20% tariff during a transition period, with no tariff applied if they also agree to lower prices to levels comparable to those paid in other developed nations – often referred to as “most favored nation” pricing.

If drug production is not relocated to the U.S. Within four years, the full 100% tariff will be implemented. The tariffs will take effect on July 31 for some companies and September 29 for others, depending on company size. USA Today reports that multiple companies have already agreed to deals to lower prices and bring production to the U.S.

Exemptions to the Tariffs

Several countries are exempt from the tariffs due to existing trade deals with the United States. These include the European Union, Japan, South Korea, Switzerland, and the United Kingdom. The Associated Press notes that the administration has already reached 17 pricing deals with major drugmakers, 13 of which have been signed.

Adjustments to Steel and Aluminum Tariffs

Alongside the pharmaceutical tariffs, the Trump administration also announced changes to how tariffs are calculated on imported raw materials made from steel, aluminum, and copper, as well as on imported products containing these metals. Politico details these adjustments, which represent another shift in the administration’s trade strategy.

Rationale Behind the Tariffs

A senior White House official stated that the tariffs are intended to ensure the United States is not overly reliant on other countries for essential medications, particularly in the event of global supply chain disruptions. The order signed by President Trump highlights that approximately 53% of patented drugs distributed in the U.S. Are currently manufactured outside the country. CNBC reports that the administration aims to protect and secure the domestic drug supply.

Potential Impact on Drug Prices

Experts caution that the steep tariffs could potentially increase drug prices for consumers. Even as the administration hopes the tariffs will incentivize domestic production and lower prices in the long run, the immediate effect could be higher costs. Roughly 90% of U.S. Drug prescriptions are for generic medications, which are not directly affected by these tariffs.